Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Bravelle, Fostimon; Belgium: Fostimon; Bulgaria: Bravelle, Fostimon; Czech Republic: Bravelle, Fostimon; Denmark: Bravelle, Fostimon; Estonia: Bravelle; Finland: Fostimon; France: Fostimon; Germany: Bravelle, Fertinorm; Greece: Folligon, Metrodin; Hungary: Bravelle; Ireland: Bravelle, Fostimon; Italy: Metrodin; Latvia: Bravelle; Lithuania: Bravelle; Netherlands: Bravelle, Fostimon; Poland: Bravelle, Fostimon, Metrodin; Portugal: Bravelle, Fostimon; Romania: Bravelle; Slovakia: Bravelle, Fostimon; Slovenia: Bravelle; Spain: Bravelle, Fostipur; Sweden: Bravelle, Fostimon.

North America

Canada: Bravelle; USA: Bravelle.

Latin America

Brazil: Metrodin; Mexico: Fostimón.

Drug combinations


Urofollitropin: A preparation of purified extract of human post-menopausal urine containing follicle-stimulating hormone (FSH). CAS-97048-13-0 (1987).

Pharmacologic Category

Hormones and Synthetic Substitutes; Gonadotropins. Ovulation Stimulator. (ATC-Code: G03GA04).

Mechanism of action

A preparation of highly purified follicle-stimulating hormone (FSH) extracted from urine of postmenopausal women. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure.

Therapeutic use

Ovulation induction in patients who previously received pituitary suppression. Development of multiple follicles with assisted reproductive technologies.

Pregnancy and lactiation implications

Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births reported. Excretion in breast milk unknown (not recommended in nursing women).

Unlabeled use


Hypersensitivity to follitropins or any component of the formulation. High levels of FSH indicating primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Presence of any cause of infertility other than anovulation. Presence of organic intracranial lesion (e.g. pituitary tumor). Abnormal vaginal bleeding of undetermined origin. Ovarian cysts or enlargement not due to polycystic ovary syndrome. Pregnancy.

Warnings and precautions

Ovarian enlargement might occur and may be accompanied by abdominal distention or abdominal pain. Ovarian hyperstimulation syndrome, develops rapidly within 24 hours to several days and generally occurs during 7-10 days immediately following treatment. Hemoconcentration associated with fluid loss into abdominal cavity occurred. Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) reported. Thromboembolic events reported. Products may contain lactose. Multiple births may result.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart